Identifying additional benefits could help us understand the biological pathways influenced by these drugs and uncover new opportunities for disease prevention and treatment, including cancer prevention. Aparna Kamat, MD Kamat is the senior author of a new study published in the journal Annals of Oncology that found a potential link between taking GLP-1 medications, such as Ozempic , Wegovy , Zepbound , and Mounjaro , and a decrease in the overall risk of developing obesity-related cancers in people without diabetes
Clinical evidence on cancer endpoints has been limited and heterogeneous, creating a clear knowledge gap despite strong biologic plausibility
Still or sparkling water provides hydration without calories, sugar or digestive burden, and helps support overall wellbeing
Patient Access Economics and Healthcare Coverage Framework Insurance Coverage, Employer Benefits, and Global Reimbursement Pathways Define GLP-1 Weight Loss Drug Market Commercial Scalability The patient access landscape for GLP-1 weight loss drugs is undergoing rapid payer policy evolution, with commercial coverage expanding from 26% of U.S
